



► BIOPHARMA POOL

Steven Ertel Dr. Matthew Sherman ACCELERON PHARMA ANNOUNCES EXECUTIVE APPOINTMENTS AND PROMOTIONS



Steven Ertel



Dr. Matthew Sherman

Accelaron Pharma, a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic candidates that regulate cellular growth and repair, has made two executive promotions and appointments from within the organization. Steven Ertel has been named executive VP and chief operating officer; he previously held the title of senior VP and chief business officer. In addition, Matthew Sherman, M.D., has been promoted to executive VP and chief medical officer. Dr. Sherman joined Accelaron in 2006 and immediately made key contributions such as recognizing sotatercept as a potential treatment for anemia.

Christopher Guiffre CERULEAN APPOINTS PRESIDENT AND CEO



Christopher Guiffre

Cerulean Pharma, which uses its dynamic tumor targeting platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations, has named Christopher Guiffre, president and CEO. Mr. Guiffre has served as Cerulean's chief operating officer since 2014.

Andrew Hirsch BIND THERAPEUTICS ANNOUNCES MANAGEMENT CHANGES



Andrew Hirsch

BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has named Andrew Hirsch as acting president and CEO.


Mr. Hirsch was formerly BIND's chief operating officer and chief financial officer.

He replaces Scott Minick, who remains a member of BIND's board of directors.

BIND intends to announce a permanent CEO shortly.

► BIOTECH POOL

Anna Protopapas MERSANA APPOINTS PRESIDENT AND CEO



Anna Protopapas

Mersana, which engineers antibody-drug conjugates (ADCs) that maximize the potential of new and established therapeutic classes, has named Anna Protopapas as president and CEO. Ms. Protopapas was most recently president of Millennium Pharmaceuticals.

Dr. Benjamin Yerxa ENVISIA THERAPEUTICS NAMES PRESIDENT



Benjamin Yerxa

Envisia Therapeutics has named Benjamin Yerxa, Ph.D., as the president. Dr. Yerxa joined Liquidia Technologies in August 2012 and was critical to the company's formation of Envisia in November 2013 where he has since served in the dual role

of chief scientific officer for both companies.

► CRO POOL

Etienne Drouet SYNERACTHCR EXPANDS SENIOR MANAGEMENT TEAM



Etienne Drouet

SyneractHCR, a full-service, international CRO, has hired Etienne Drouet as VP, strategic development. This is a new position created to augment the depth of the company's oncology and complex trial expertise.

Mr. Drouet joins SyneractHCR from Premier Research where he was executive director, global oncology.

Elgar Peerschke QUINTILES NAMES PRESIDENT, ADVISORY SERVICES



Elgar Peerschke

Quintiles has appointed Elgar Peerschke to serve as president, advisory services. In this role, Mr. Peerschke is responsible for the continued development and delivery of its related services. Bringing more than 25 years of experience to Quintiles,

Mr. Peerschke joins Quintiles from Bain & Company, a global business consulting firm, where he was a senior partner in its global healthcare practice group and a leading client service partner.

► TECHNOLOGY POOL

Dr. Tim Gustafson APERVITA EXPANDS MANAGEMENT TEAM



Dr. Tim Gustafson

Apervita, a health analytics community, has appointed Tim Gustafson, M.D., as chief content officer. In his role, Dr. Gustafson is responsible for leading Apervita's author community and oversees the growth of content offered on Apervita's market for health analytics, including algorithms, measures, pathways, protocols, and data focused on critical health areas, such as chronic disease management, preventable adverse events, readmissions, cancer, early warning, quality, and safety.

Before joining Apervita, Dr. Gustafson spent 10 years as a health strategy and innovation consultant as a principal and expert principal at Innosight, a global innovation firm.

Alan Mateo VEEVA NAMES EXECUTIVE VP, GLOBAL SALES



Alan Mateo

Veeva Systems has hired Alan Mateo as executive VP of global sales. Mr. Mateo is charged with leading Veeva's worldwide salesforce and reports to Veeva's Co-founder and CEO Peter Gassner.

Mr. Mateo brings more than 30 years of experience in enterprise software. He spent the last 10 years selling clinical cloud solutions in life sciences while head of worldwide field operations at Medidata Solutions.

Dr. Colleen McHorney ERT EXPANDS SCIENTIFIC CONSULTING GROUP



Dr. Colleen McHorney

ERT, a global solution provider for high-quality patient safety and efficacy endpoint data collection, has expanded its cardiac safety, respiratory, and clinical outcome assessment (COA)/electronic COA

(eCOA) consulting group with the addition of Colleen McHorney, Ph.D., as senior scientist in its COA consulting group. With 30 years of experience, Dr. McHorney's expertise spans from qualitative research for concept elicitation and patient comprehension to advanced classical and modern psychometric techniques for item analysis and scale validation. ^{PV}



FOR BONUS CONTENT
USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0515-Pool



► BIOPHARMA POOL

John Ferraro
Walter Grubb
Dr. Wendy Levin

FATE THERAPEUTICS EXPANDS AND STRENGTHENS LEADERSHIP TEAM

Fate Therapeutics, a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, has promoted John Ferraro to the newly created position of VP, clinical operations. Mr. Ferraro joined Fate Therapeutics in February 2013, and he is responsible for the company's clinical operations and data management functions.

In other company news, Walter Grubb has joined Fate as VP, business development.

Mr. Grubb's responsibilities include the assessment, valuation and licensing of business opportunities for the company.

Mr. Grubb was previously executive director of business development and commercial operations at Ambit Biosciences, where he was responsible for multiple partnership transactions, provided commercial leadership for product candidates spanning a range of indications and stages of development.

Finally, Wendy Levin, M.D., has joined the company as VP, clinical development. Dr. Levin plays a critical role spearheading the company's clinical development of Prohema in patients with hematologic malignancies and rare genetic disorders. Previously, she was VP of clinical development and medical affairs at MEI Pharma.

Dr. Steven Stein **INCYTE APPOINTS CHIEF MEDICAL OFFICER**

Incyte has named Steven Stein, M.D., senior VP and chief medical officer. Dr. Stein was formerly senior VP, US clinical development and medical affairs at Novartis Oncology US.

He is responsible for clinical and medical strategy and operations across Incyte's extensive oncology portfolio.

► BIOTECH POOL

Dr. John Caminis **DERMA SCIENCES NAMES CHIEF MEDICAL OFFICER**

Derma Sciences, a tissue regeneration company focused on advanced wound and burn care, has appointed John Caminis, M.D., to the newly created position of chief medical officer. Dr. Caminis is a seasoned pharmaceutical physician with particular expertise in clinical drug development.

Since 2011 he served as senior medical director in the immunology, and later in the bone patient value unit at UCB, a global biopharmaceutical company.

► GENOMICS POOL

Dr. Laurence Reid **WARP DRIVE BIO APPOINTS CEO**

Warp Drive Bio, a life-sciences company using proprietary genomic technology to transform the discovery and development of therapeutics derived from natural products, has named Laurence Reid, Ph.D., CEO.

Dr. Reid succeeds CEO and co-founder Gregory Verdine, Ph.D., who continues to serve the company as president and chief scientific officer, as well as the chairman of Warp Drive Bio's scientific advisory board.

► GENETICS POOL

Dr. Richard Scheller **23ANDME NAMES CHIEF SCIENTIFIC OFFICER**

23andMe has appointed Richard Scheller, Ph.D., as chief science officer and head of its new therapeutics group. Previously, Dr. Scheller spent 14 years at Genentech, where he served as executive VP of research and early development.

The newly formed therapeutics group is using the 23andMe database and its human genetic data as the starting point for identifying new therapies for both common and rare diseases.

Dr. Scheller is working with existing 23andMe researchers and leading the recruiting efforts to

build an expanded team of scientists and genetic researchers.

► AGENCY POOL

Dr. Kiran Ghouri **Stephanie Smith** **AXON COMMUNICATIONS EXPANDS NY OFFICE**

New York specialist healthcare consultancy AXON has added two new employees to its growing practice. Kiran Ghouri, Pharm.D., joins the firm as a medical writer and Stephanie Smith joins AXON as a senior program manager. Both hires bring a great deal of knowledge, experience, and talent to our team.

Timothy Goddard **Michelle Gross** **Michelle Strier** **SPECTRUM EXPANDS LEADERSHIP TEAM**

In conjunction with opening a new office in New York, Spectrum, an independent communications firm specializing in health, and consumer, and life sciences, has named three industry veterans to senior positions.

Timothy Goddard has been named senior VP of GlobalHealthPR, and brings extensive experience as a global communications counselor in preparing senior spokespeople and driving communications programs around pivotal trials, regulatory milestones, issues, disease awareness campaigns, and advocacy partnerships.

Spectrum's New York office is led by managing director Michelle Gross, a veteran health communications strategist with more than 16 years of experience in the planning and implementation of consumer and professional communications programs for pharmaceutical companies.

Service to Spectrum's global client base is enhanced with the addition of Michelle Strier as senior VP. Ms. Strier has worked with government agencies, hospitals, health nonprofits, large pharmaceutical companies, and small biotechs, and has led diverse teams in the development of strong, successful client programs.

Frank Saia **CMK SELECT EXPANDS LEADERSHIP TEAM**

CMK Select, a consulting firm for the pharmaceutical and life-sciences industries, has added Frank Saia to its executive leadership team. In his new role as VP, business development, Mr. Saia is responsible for driving revenue and growth through building the business development organization, developing and managing the marketing strategy, defining new service offerings, and championing client engagement and retention. **PV**

eye for pharma
6th Annual
**Sales & Multichannel
Canada 2015**
17th - 18th June 2015
Doubletree Toronto Downtown

Speakers include:

AstraZeneca
life inspiring ideas

Lilly

LEO

NOVARTIS

Lundbeck

Customer Experience in Health Summit

Book before
March 6
for only
£395
(saving £400)

May 12 | 2015 | Altitude | SW1 | London

Speakers:



Martin Bellingham
Head of Customer Insight
AXA



Andrew Hancock
Head of Customer Services & Revenue
Management | **EDF Energy**



Andrew Archibald
Director of Customer Experience
Travelodge



Detlev Parow
Head of Department of Care
Management Development
DAK Gesundheit



James Baker
Head of Insight, Vitality
Pru Health/Vitality



Marc Barlow
Head of Global Strategic Marketing
GE Healthcare



Leon de Gilde
Director of Operations
Baxter



Gabor Purman
Senior Project Leader Customer
Experience | **GSK**

Support customers to drive behaviour change and increase product ROI.



Session One

Strategy

You'll understand the 'cause & effect' relationship with marketing, sales, patient outcomes and CX. You'll learn how to create market uplift by improving product value through applying a robust CX strategy to your commercial campaigns.



Session Two

Insight

You'll know where Voice of Customer, Voice of Employee, Voice of Process & Point of Value applies in your CX planning and delivery.



Session Three

Digital

Learn how other verticals apply Customer Success tactics, and how these have huge applications for pharma's CX commercial activities.

See all 18 speakers and detailed sessions at createhealth.io/cx

create health.io/cx